274 related articles for article (PubMed ID: 12593623)
1. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index.
Tanaka Y; Hongo K; Tada T; Sakai K; Kakizawa Y; Kobayashi S
J Neurosurg; 2003 Feb; 98(2):359-65. PubMed ID: 12593623
[TBL] [Abstract][Full Text] [Related]
2. [Natural history study of postoperative residual non-functioning pituitary adenomas].
Wu ZB; Chen Y; Lü QP; Wang CD; Su ZP; Wu JS; Zheng WM; Zhuge QC
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(9):597-600. PubMed ID: 20450781
[TBL] [Abstract][Full Text] [Related]
3. MIB-1 labeling index correlated with magnetic resonance imaging detected tumor volume doubling time in pituitary adenoma.
Hsu CY; Guo WY; Chien CP; Ho DM
Eur J Endocrinol; 2010 Jun; 162(6):1027-33. PubMed ID: 20231369
[TBL] [Abstract][Full Text] [Related]
4. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.
Šteňo A; Bocko J; Rychlý B; Chorváth M; Celec P; Fabian M; Belan V; Šteňo J
Acta Neurochir (Wien); 2014 Mar; 156(3):451-61; discussion 461. PubMed ID: 24452592
[TBL] [Abstract][Full Text] [Related]
5. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
6. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression.
Widhalm G; Wolfsberger S; Preusser M; Fischer I; Woehrer A; Wunderer J; Hainfellner JA; Knosp E
J Neurosurg; 2009 Sep; 111(3):563-71. PubMed ID: 18991501
[TBL] [Abstract][Full Text] [Related]
7. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
[TBL] [Abstract][Full Text] [Related]
8. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.
Losa M; Mortini P; Barzaghi R; Ribotto P; Terreni MR; Marzoli SB; Pieralli S; Giovanelli M
J Neurosurg; 2008 Mar; 108(3):525-32. PubMed ID: 18312100
[TBL] [Abstract][Full Text] [Related]
9. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
11. Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking.
Losa M; Valle M; Mortini P; Franzin A; da Passano CF; Cenzato M; Bianchi S; Picozzi P; Giovanelli M
J Neurosurg; 2004 Mar; 100(3):438-44. PubMed ID: 15035279
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological correlates of extrasellar growth patterns in pituitary adenomas.
Sarkar S; Chacko AG; Chacko G
J Clin Neurosci; 2015 Jul; 22(7):1173-7. PubMed ID: 25979255
[TBL] [Abstract][Full Text] [Related]
13. Tumor shrinkage after transsphenoidal surgery for nonfunctioning pituitary adenoma.
Berkmann S; Schlaffer S; Buchfelder M
J Neurosurg; 2013 Dec; 119(6):1447-52. PubMed ID: 24074495
[TBL] [Abstract][Full Text] [Related]
14. Tumor shrinkage assessed by volumetric MRI in long-term follow-up after fractionated stereotactic radiotherapy of nonfunctioning pituitary adenoma.
Kopp C; Theodorou M; Poullos N; Jacob V; Astner ST; Molls M; Grosu AL
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1262-7. PubMed ID: 21530099
[TBL] [Abstract][Full Text] [Related]
15. Impact of ultra-low-field intraoperative magnetic resonance imaging on extent of resection and frequency of tumor recurrence in 104 surgically treated nonfunctioning pituitary adenomas.
Hlavica M; Bellut D; Lemm D; Schmid C; Bernays RL
World Neurosurg; 2013 Jan; 79(1):99-109. PubMed ID: 23043996
[TBL] [Abstract][Full Text] [Related]
16. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
17. Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma.
Sheehan JP; Kondziolka D; Flickinger J; Lunsford LD
J Neurosurg; 2002 Dec; 97(5 Suppl):408-14. PubMed ID: 12507066
[TBL] [Abstract][Full Text] [Related]
18. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
19. Changes in the volume of residual pituitary adenomas in patients with adult-onset growth hormone deficiency during replacement therapy with the recombinant human growth hormone.
Finkenstedt G; Höfle G; Pallua A; Sailer U; Gasser RW
Wien Klin Wochenschr; 1999 Nov; 111(21):887-90. PubMed ID: 10599151
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.
Rudnik A; Zawadzki T; Gałuszka-Ignasiak B; Bazowski P; Duda I; Wojtacha M; Rudnik AI; Krawczyk I
Minim Invasive Neurosurg; 2006 Feb; 49(1):10-4. PubMed ID: 16547875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
